Houston Methodist researchers will be a major part of an upcoming national consortium to develop vaccines against two of the most damaging strains of herpesvirus. The consortium is focused on fighting the Ꞵ- and γ- herpesviruses, which are the strains that include common diseases like Epstein-Barr and cytomegalovirus.
Jimmy Gollihar, Ph.D. is the head of the Antibody Discovery & Accelerated Protein Therapeutics (ADAPT) laboratory at the Houston Methodist Research Institute and will be a co-principal investigator. He will serve as an expert on artificial intelligence and machine learning, using his knowledge in these fields to create gene sequences that encode viral antigens for the mRNA vaccines the consortium is attempting to develop.
Houston Methodist is proud that Gollihar and the ADAPT lab are contributing to this research initiative and helping to fight against these devastating viruses. It reflects the high quality of work that our researchers do in the quest to make the world a healthier place and shows that their dedication has made them leaders in the field of medicine.
Come lead with us at Houston Methodist Academic Institute: https://www.houstonmethodistcareers.org/locations-academic-institute.html
